arrow
A

Akihide Yoshimi

national cancer center research institute
H指数:35
被引数:5,703

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

作者更正: 组织细胞性肿瘤中CSF1R和其他受体酪氨酸激酶的激活突变

2026-09-010
PRE
IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs

IL-6驱动的POU2AF1和ELL2是骨髓瘤特异转录和剪接程序的关键调控因子

2026-04-070
OAAI
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma
2024-09-170
OAAI
Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization
2024-08-280
OAAI
SRSF2 plays an unexpected role as reader of m5C on mRNA, linking epitranscriptomics to cancer

SRSF2作为mRNA上m5C的阅读器起着意想不到的作用,将epitranscripttomics与癌症联系起来

2023-12-0118
OAAI
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
2023-11-1811
OAAI
An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress

Atr-primpol途径赋予对致癌KRAS诱导和异染色质相关复制应激的耐受性

2023-08-1711
OAAI
Genetic basis for iMCD-TAFRO
2020-02-1218
OAAI
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
2019-11-25138
OAAI
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2019-10-0167
OAAI